Category Archives: Cancer Therapies

Oncotarget With Precision

Due to the uptick in technological advances, humankind remains lazier than ever. To expound further, humankind remains less reliant on themselves to get tasks done. As a result, they exercise less. Due to this lack of exercise, humankind finds themselves susceptible to numerous health problems. To name a few, these include obesity, diabetes, heart attacks, strokes, and cancer. With that being said, humankind’s anatomy remains unable to combat such ailments without exercising and eating healthy. Therefore, it remains pertinent for people to incorporate these vices into their regular daily regimen. With that being said, it would greatly reduce the risk of obtaining such ailments. In particular, cancer remains a condition that kills millions of people each year. This remains attributed to things such as smoking.

Although people cannot cure all forms of cancer, significant advancements have taken place. Moreover, companies such as Oncotarget have contributed significantly to finding cures for cancer. For those unaware, Oncotarget remains an industry leader. Moreover, Oncotarget remains a peer-reviewed online medical journal. Furthermore, the publication receives updates on a weekly basis. Also, the publication focuses its efforts on creating cures for cancer. In other words, the company focuses on all things pertaining to oncology. With that being said, the company began its operations in 2010 and remains published by Impact Journals. In addition, the publication includes two main editors. These include Mikhail Blagosklonny and Andrei V.

When it comes to reviewing articles, the process remains simple. It works by requiring authors to provide reputable references to other recent papers in the journal. In addition, the publication outlines its submission requirements. Prior to submitting a manuscript for publication, it remains pertinent for authors to read the instructions. When an author submits their manuscript to the publication, it implies that they accept the publication’s terms of an agreement. In addition, Mikhail Blagosklonny remains crucial to the success of the publication. As a scientist who has studied cancer for decades, Blagoskolonny remains in a position to manage the publication. In addition, he also served as a professor of oncology in New York at the Roswell Park Cancer Institute.

To know more click here

 

 

Clay Siegall: A Legend in Cancer Therapies

Clay Siegall founded Seattle Genetics in 1998. The Company is a Bio-Tech firm that deals with targeted therapies for diseases that have not seen any improvements in the past years.

Clay is the C.E.O of the Seattle Genetics and has led the Company to achieve great success. He led the company to develop its first antibody conjugate. This was the first FDA approved drug.

Seattle Genetics has also created 20 drugs with renowned drug manufacturers. Seattle Genetics has grown to become a force of nature in the Cancer industry. Siegall has positioned the Company to become a voice of authority in the 21st century.

Clay Siegall attended the University of Maryland where he graduated with a Bachelor of Science in Zoology. He later received a Ph.D. in Genetics from the University of Washington.

From a young age, Clay has been interested in Medicine and the technology to overcome diseases. In an interview, Clay said that he developed an interest in Cancer after he saw a family member go through a brutal experience with cancer.

While money was a great motivation for him pursuing launching his Company, Clay said he wanted to create an alternative therapy to alleviate the pain of cancer and chemotherapy.

The Company raises its money from the drugs that they have developed. Seattle also generates revenue from the partnerships and licenses of their technologies. According to Clay, the company became successful and profitable after ten years of in the industry. When the Company was launched, Clay managed to get $675 million through private and public finances.

Unlike most businesses, Seattle uses a unique marketing strategy to promote their services. The team spends a significant amount of time to negotiate contracts. They have also gained a great legal team.

Before launching the Company, Clay worked for the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997. Prior to that Clay worked with the National Cancer Institute. Clay also served as a member of the Board of Director of the Alder BioPharmaceuticals.

Clay is an author and published over 70 publications. He also holds 15 patents.